Where does Janssen Sciences Ireland Unlimited Company rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Janssen Sciences Ireland Unlimited Company ranks #5,687 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Janssen Sciences Ireland Unlimited Company hold?

Janssen Sciences Ireland Unlimited Company holds 60 US utility patents granted between 2019 and 2025, spanning 11 technology areas.

What is Janssen Sciences Ireland Unlimited Company's Innovation Score?

Janssen Sciences Ireland Unlimited Company has an Innovation Score of 40.0 out of 100 (top 37% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Janssen Sciences Ireland Unlimited Company's patent grant rate increasing or decreasing?

Janssen Sciences Ireland Unlimited Company's recent grant velocity is +643% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Janssen Sciences Ireland Unlimited Company's patents?

Janssen Sciences Ireland Unlimited Company's patents average 16.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Janssen Sciences Ireland Unlimited Company

Q: What technology areas does Janssen Sciences Ireland Unlimited Company focus on?

Janssen Sciences Ireland Unlimited Company's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 52 patents, ranking #338 of 6,058 assignees active in that subclass. Grants appear in 11 CPC subclasses total.

Q: How is the Janssen Sciences Ireland Unlimited Company patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO PatentsView assignee record - 60 granted patents across 11 technology areas, recorded in grant years 2019–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Janssen ranks #5,687 of 49,997 tracked US assignees by granted-patent volume, with 60 patents across 11 technology areas.

#5,687
of 49,997 US assignees by volume: Top 37%
by Innovation Score (40.0/100): 16.8
avg claims per patent: +643%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R5687 · Foreign Corporation #5,687 · 60 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL

GRANTS-SMALL 60 grants
UPPER-Q #5,687/49,997
PHOTO-FINISH Insurance Services…
CPC-FOCUS A61P · 11 areas
INNOV-THIN 40.0/100
CLAIMS-RICH 16.8 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-SURGE +643% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Insurance Services Office, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Janssen’s 40.0 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 14.2 pts (36%) Velocity 4.0 pts (10%) Breadth 11.7 pts (29%) Claim depth 10.1 pts (25%)

Qualcomm Incorporated · highest

85
Antares Pharma · near

40
Hosokawa Yoko · near

40
Janssen Sciences… · this assignee

40
Jiangsu Midea… · near

40
Luxottica S R L · near

40
3D Lighting… · lowest

7

What this shows Janssen's Innovation Score is 40.0/100 (top 37% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Janssen?

Each dot is one of Janssen’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Janssen’s own 16.8 claims/patent is ABOVE the 16.4 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Janssen vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Janssen's grants concentrate

Janssen Sciences Ireland Unlimited Company is a focused PatentsView assignee: 11 CPC subclasses with 86.7% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2020 (15 grants) versus a trough of 5 in 2024. By volume, Janssen sits between ITT Italia S.r.l. and Kongsberg Automotive AB.

Janssen's three-year grant acceleration

From 2019–2021 to 2022–2024, Janssen Sciences Ireland Unlimited Company moved from 37 to 22 grants (0.59x the prior three-year total, a multiple, not a CAGR). See the growth leaderboard.

ITT Italia S r l

60
Insurance Service…

60
Intellectual Vent…

60
Juki

60
Kepco Nuclear Fuel

60
Kimree Hi-tech

60
Knauf Insulation

60
Kongsberg Automot…

60
Janssen Sciences… ◀

60

What this shows Janssen holds 60 patents at rank #5,687, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Janssen

By rank, the assignees closest to #5,687 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Janssen's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Janssen, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Janssen ranks #338 of 6,058 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (40 here).

Luxottica S.R.L. 40 Jiangsu Midea Cleaning Appliances Co., Ltd. 40 Antares Pharma, Inc. 40 Hosokawa Yoko Co., Ltd. 40

Similar claim depth

Nearest assignees by average claims per patent (16.8 here).

MAC Trailer Manufacturing, Inc. 16.8 avg Provisur Technologies, Inc. 16.8 avg Hamilton Bonaduz AG 16.8 avg Hyliion Inc. 16.8 avg

Janssen's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

40 Top 37% higher than 63% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2019–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.

View data table

Janssen Sciences Ireland Unlimited Company patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2019	7	11.7%
2020	15	25.0%
2021	15	25.0%
2022	10	16.7%
2023	7	11.7%
2024	5	8.3%
2025partial year	1	1.7%

Which technologies does Janssen Sciences Ireland Unlimited Company patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 52

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 42

C07D - Heterocyclic Compounds 31

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 11

C07K - Peptides 9

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 3

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 2

A61L - Methods OR Apparatus FOR Sterilising Materials OR Objects IN GENERAL; Disinfection, Sterilisation OR Deodorisation OF AIR; Chemical Aspects OF Bandages, Dressings, Absorbent Pads OR Surgical ARTICLES; Materials FOR Bandages, Dressings, Absorbent Pads OR Surgical Articles 2

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 1

A61B - DIAGNOSIS; SURGERY; Identification 1

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy 1

Top 11 of 11 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Janssen Sciences Ireland Unlimited Company's patent record in context - here's where to go next.

Janssen Sciences Ireland Unlimited Company's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 86.7% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #5,687 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Janssen Sciences Ireland Unlimited Company against ITT Italia S.r.l., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 40.0/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.